Drug Type Small molecule drug |
Synonyms Cyabin, Orange Crush, 比生群 + [4] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date FR (01 Jan 1990), |
Regulation- |
Molecular FormulaC22H23ClN8 |
InChIKeyHBSXKBIYGYFNRF-UHFFFAOYSA-N |
CAS Registry71439-68-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Myeloid Leukemia | FR | 01 Jan 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematopoietic stem cell transplantation | Phase 2 | IL | 18 Jul 2019 | |
Refractory acute myeloid leukemia | Phase 2 | IL | 18 Jul 2019 | |
Relapsing acute myeloid leukemia | Phase 2 | IL | 18 Jul 2019 | |
Chronic Myelomonocytic Leukemia | Phase 1 | AU | 29 Jul 2022 | |
Extramedullary Plasmacytoma | Phase 1 | AU | 29 Jul 2022 | |
High Risk Myelodysplastic Syndrome | Phase 1 | AU | 29 Jul 2022 |
Phase 2 | 10 | jnbliazlip(dmszxhnzqy) = acyxllmfkb nembbszkwd (fbemubmfti ) | Positive | 01 Feb 2021 |